News
PRTA
10.31
-1.81%
-0.19
Weekly Report: what happened at PRTA last week (0406-0410)?
Weekly Report · 21h ago
Prothena files Form 3 for Chief Strategy Officer Anne Evans Kingston
Reuters · 3d ago
Prothena names Annie Kingston as Chief Strategy Officer
TipRanks · 3d ago
Prothena promotes Annie Kingston to chief strategy officer amid legal chief transition
Reuters · 3d ago
Prothena Announces Leadership Team Updates
Barchart · 3d ago
Weekly Report: what happened at PRTA last week (0330-0403)?
Weekly Report · 04/06 10:06
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
NASDAQ · 03/30 16:16
Weekly Report: what happened at PRTA last week (0323-0327)?
Weekly Report · 03/30 10:06
Prothena announced its annual general meeting of shareholders
Reuters · 03/27 22:37
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
NASDAQ · 03/27 15:30
When Can We Expect A Profit From Prothena Corporation plc (NASDAQ:PRTA)?
Simply Wall St · 03/27 10:17
Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Spyre Therapeutics (SYRE) and Prothena (PRTA)
TipRanks · 03/23 12:01
Weekly Report: what happened at PRTA last week (0316-0320)?
Weekly Report · 03/23 10:02
Prothena partners present prasinezumab and BMS-986446 clinical study updates at AD/PD 2026
Reuters · 03/21 20:05
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Barchart · 03/21 15:05
Weekly Report: what happened at PRTA last week (0309-0313)?
Weekly Report · 03/16 10:02
Prothena (PRTA): Partner-Funded, Milestone-Rich Pipeline De-Risks Lead Programs and Supports Buy Rating
TipRanks · 03/10 12:25
Prothena Corporation plc publishes corporate overview presentation on protein dysregulation disease pipeline and USD 308.4 million cash position
Reuters · 03/09 20:22
Prothena achieves $50M clinical milestone payment from Novo Nordisk
TipRanks · 03/09 20:11
Prothena earns USD 50 million milestone payment from Novo Nordisk
Reuters · 03/09 20:11
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.